Cited 5 times in
Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with Type 2 diabetes treated with rosiglitazone
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 안철우 | - |
dc.contributor.author | 이현철 | - |
dc.contributor.author | 차봉수 | - |
dc.contributor.author | 강은석 | - |
dc.date.accessioned | 2015-04-24T16:38:50Z | - |
dc.date.available | 2015-04-24T16:38:50Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0742-3071 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/103907 | - |
dc.description.abstract | AIMS: To investigate the effect of two common ATP-binding cassette transporter 1 (ABCA1) polymorphisms (rs4149263 and rs2020927) on atherogenic dyslipidaemia in Korean Type 2 diabetic patients who were treated with rosiglitazone. PATIENTS AND METHODS: Two hundred and fifty-six patients with Type 2 diabetes who had never previously received peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists or lipid-lowering treatment were treated with 4 mg of rosiglitazone daily for 12 weeks without any adjustment to their glucose-lowering regimen. The primary outcome was the change in atherogenic index of plasma (AIP), calculated as log [triglyceride (mmol/l)/high-density lipoprotein cholesterol (mmol/l)], before and after rosiglitazone treatment. The effect of rosiglitazone on the change in AIP was compared across the ABCA1 single nucleotide polymorphisms (SNPs) rs41429263 and rs2020927. RESULTS: Before adjustment, the change in AIP at 12 weeks was significantly different across the rs4149263 genotypes [median (interquartile range): -0.05 (-0.21, 0.09) for TT; 0.02 (-0.09, 0.17) for TC; and 0.11 (0.03, 0.25) for CC; P = 0.003], but not across the rs2020927 [-0.04 (-0.18, 0.10) for TT; 0.03 (-0.17, 0.15) for TC; and -0.03 (-0.13, 0.10) for CC; P = 0.401]. After controlling for age, gender and duration of diabetes, the presence of the C-allele was significantly associated with an increase in AIP by 0.13 [95% confidence interval (CI), 0.04-0.21; P = 0.003]. This association did not change significantly when body mass index and pretreatment metabolic parameters were additionally controlled for (the change in AIP: 0.14; 95% CI, 0.04-0.24; P = 0.007). CONCLUSIONS: The ABCA1 SNP rs4149263 may be associated with the change in atherogenic lipid profile in Type 2 diabetes treated with rosiglitazone. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | DIABETIC MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Blood Glucose/metabolism* | - |
dc.subject.MESH | Cholesterol, HDL/metabolism | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/drug therapy* | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/genetics | - |
dc.subject.MESH | Dyslipidemias/drug therapy* | - |
dc.subject.MESH | Dyslipidemias/metabolism | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypoglycemic Agents/therapeutic use* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | PPAR gamma/metabolism* | - |
dc.subject.MESH | Thiazolidinediones/administration & dosage | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Triglycerides/metabolism | - |
dc.subject.MESH | Young Adult | - |
dc.title | Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with Type 2 diabetes treated with rosiglitazone | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | S. E. Park | - |
dc.contributor.googleauthor | E. S. Kang | - |
dc.contributor.googleauthor | D. H. Kim | - |
dc.contributor.googleauthor | S. K. Kim | - |
dc.contributor.googleauthor | J. H. Lee | - |
dc.contributor.googleauthor | C. W. Ahn | - |
dc.contributor.googleauthor | H. C. Lee | - |
dc.contributor.googleauthor | B. S. Cha | - |
dc.identifier.doi | 10.1111/j.1464-5491.2009.02728.x | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00630 | - |
dc.contributor.localId | A02270 | - |
dc.contributor.localId | A03084 | - |
dc.contributor.localId | A03301 | - |
dc.contributor.localId | A03996 | - |
dc.contributor.localId | A01521 | - |
dc.contributor.localId | A00068 | - |
dc.relation.journalcode | J00726 | - |
dc.identifier.eissn | 1464-5491 | - |
dc.identifier.pmid | 19538231 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/j.1464-5491.2009.02728.x/abstract | - |
dc.subject.keyword | atherogenic dyslipidaemia | - |
dc.subject.keyword | ATP‐binding cassette transporter 1 | - |
dc.subject.keyword | genetic association | - |
dc.subject.keyword | rosiglitazone | - |
dc.contributor.alternativeName | Ahn, Chul Woo | - |
dc.contributor.alternativeName | Lee, Hyun Chul | - |
dc.contributor.alternativeName | Cha, Bong Soo | - |
dc.contributor.alternativeName | Kang, Eun Seok | - |
dc.contributor.affiliatedAuthor | Ahn, Chul Woo | - |
dc.contributor.affiliatedAuthor | Lee, Hyun Chul | - |
dc.contributor.affiliatedAuthor | Cha, Bong Soo | - |
dc.contributor.affiliatedAuthor | Kang, Eun Seok | - |
dc.citation.volume | 26 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 577 | - |
dc.citation.endPage | 581 | - |
dc.identifier.bibliographicCitation | DIABETIC MEDICINE, Vol.26(6) : 577-581, 2009 | - |
dc.identifier.rimsid | 37874 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.